260 related articles for article (PubMed ID: 24166935)
1. Subclassification of "atypia of undetermined significance" in thyroid fine-needle aspirates.
Wu HH; Inman A; Cramer HM
Diagn Cytopathol; 2014 Jan; 42(1):23-9. PubMed ID: 24166935
[TBL] [Abstract][Full Text] [Related]
2. Follicular lesion of undetermined significance in thyroid FNA revisited.
Walts AE; Mirocha J; Bose S
Diagn Cytopathol; 2014 Jan; 42(1):18-22. PubMed ID: 23894017
[TBL] [Abstract][Full Text] [Related]
3. Subclassification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid: distinct patterns and associated risk of malignancy.
Renshaw AA
Cancer Cytopathol; 2011 Oct; 119(5):322-7. PubMed ID: 21442771
[TBL] [Abstract][Full Text] [Related]
4. The prevalence and surgical outcomes of Hürthle cell lesions in FNAs of the thyroid: A multi-institutional study in 6 Asian countries.
Agarwal S; Bychkov A; Jung CK; Hirokawa M; Lai CR; Hong S; Kwon HJ; Rangdaeng S; Liu Z; Su P; Kakudo K; Jain D
Cancer Cytopathol; 2019 Mar; 127(3):181-191. PubMed ID: 30668897
[TBL] [Abstract][Full Text] [Related]
5. Does Hurthle cell lesion/neoplasm predict malignancy more than follicular lesion/neoplasm on thyroid fine-needle aspiration?
Pu RT; Yang J; Wasserman PG; Bhuiya T; Griffith KA; Michael CW
Diagn Cytopathol; 2006 May; 34(5):330-4. PubMed ID: 16604553
[TBL] [Abstract][Full Text] [Related]
6. Different qualifiers of AUS/FLUS thyroid FNA have distinct BRAF, RAS, RET/PTC, and PAX8/PPARg alterations.
Bellevicine C; Sgariglia R; Migliatico I; Vigliar E; D'Anna M; Nacchio MA; Serra N; Malapelle U; Bongiovanni M; Troncone G
Cancer Cytopathol; 2018 May; 126(5):317-325. PubMed ID: 29469940
[TBL] [Abstract][Full Text] [Related]
7. An institutional experience: A retrospective analysis of the effect of transitioning from follicular lesion of undetermined significance to atypia of undetermined significance with subclassified atypia on interobserver concordance, rates of neoplasia, and rates of malignancy.
Kroll-Wheeler L; Cantley R; Pang JC; Soles BS; Smola B; Jing X; Lew M
Diagn Cytopathol; 2021 Jan; 49(1):31-38. PubMed ID: 32936526
[TBL] [Abstract][Full Text] [Related]
8. Subcategorisation of AUS/FLUS thyroid lesions as per the 2017 Bethesda System for Reporting Thyroid Cytopathology: a retrospective study from a tertiary care centre analysing risk of malignancy (ROM) of the different subcategories.
Guleria P; Agarwal S; Iyer VK; Jain D; Mathur SR; Yadav D
J Clin Pathol; 2019 Nov; 72(11):771-777. PubMed ID: 31375535
[TBL] [Abstract][Full Text] [Related]
9. Hürthle cell neoplasms diagnosed by fine needle aspiration are not associated with an increased risk of malignancy.
McKee S; Wu H; Wang X; Cramer H; Lin J; Chen S
Acta Cytol; 2014; 58(3):235-8. PubMed ID: 24819535
[TBL] [Abstract][Full Text] [Related]
10. Subclassification of Bethesda Atypical and Follicular Neoplasm Categories According to Nuclear and Architectural Atypia Improves Discrimination of Thyroid Malignancy Risk.
Lim JXY; Nga ME; Chan DKH; Tan WB; Parameswaran R; Ngiam KY
Thyroid; 2018 Apr; 28(4):511-521. PubMed ID: 29596039
[TBL] [Abstract][Full Text] [Related]
11. The prediction of malignant risk in the category "atypia of undetermined significance/follicular lesion of undetermined significance" of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results.
Hyeon J; Ahn S; Shin JH; Oh YL
Cancer Cytopathol; 2014 May; 122(5):368-76. PubMed ID: 24591408
[TBL] [Abstract][Full Text] [Related]
12. Follow-up of atypia and follicular lesions of undetermined significance in thyroid fine needle aspiration cytology.
Dincer N; Balci S; Yazgan A; Guney G; Ersoy R; Cakir B; Guler G
Cytopathology; 2013 Dec; 24(6):385-90. PubMed ID: 23078633
[TBL] [Abstract][Full Text] [Related]
13. Subclassification of the Bethesda Category III (AUS/FLUS): A study of thyroid FNA cytology based on ThinPrep slides from the National Cancer Center in China.
Zhao H; Guo H; Zhao L; Cao J; Sun Y; Wang C; Zhang Z
Cancer Cytopathol; 2021 Aug; 129(8):642-648. PubMed ID: 34139103
[TBL] [Abstract][Full Text] [Related]
14. Does the fine-needle aspiration diagnosis of "Hürthle-cell neoplasm/follicular neoplasm with oncocytic features" denote increased risk of malignancy?
Giorgadze T; Rossi ED; Fadda G; Gupta PK; Livolsi VA; Baloch Z
Diagn Cytopathol; 2004 Nov; 31(5):307-12. PubMed ID: 15468114
[TBL] [Abstract][Full Text] [Related]
15. The impact of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on the rate of malignancy for atypia of undetermined significance subcategories.
Hang JF; Westra WH; Zhou AG; Cooper DS; Ali SZ
Cancer Cytopathol; 2018 May; 126(5):309-316. PubMed ID: 29424960
[TBL] [Abstract][Full Text] [Related]
16. The role of thyroid fine-needle aspiration cytology in the pediatric population: an institutional experience.
Rossi ED; Straccia P; Martini M; Revelli L; Lombardi CP; Pontecorvi A; Fadda G
Cancer Cytopathol; 2014 May; 122(5):359-67. PubMed ID: 24474727
[TBL] [Abstract][Full Text] [Related]
17. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System.
Sullivan PS; Hirschowitz SL; Fung PC; Apple SK
Cancer Cytopathol; 2014 Dec; 122(12):866-72. PubMed ID: 25078420
[TBL] [Abstract][Full Text] [Related]
18. Reclassification of cytologically atypical thyroid nodules based on radiologic features in pediatric patients.
Arva NC; Deitch SG
J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):753-60. PubMed ID: 25879311
[TBL] [Abstract][Full Text] [Related]
19. BRAF mutation detection in indeterminate thyroid cytology specimens: underlying cytologic, molecular, and pathologic characteristics of papillary thyroid carcinoma.
Ohori NP; Singhal R; Nikiforova MN; Yip L; Schoedel KE; Coyne C; McCoy KL; LeBeau SO; Hodak SP; Carty SE; Nikiforov YE
Cancer Cytopathol; 2013 Apr; 121(4):197-205. PubMed ID: 22887810
[TBL] [Abstract][Full Text] [Related]
20. Hürthle cell presence alters the distribution and outcome of categories in the Bethesda system for reporting thyroid cytopathology.
Yazgan A; Balci S; Dincer N; Kiyak G; Tuzun D; Ersoy R; Cakir B; Guler G
Cytopathology; 2014 Jun; 25(3):185-9. PubMed ID: 24024935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
